AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Analyst Downgrades for Friday: Keysight, Akero Therapeutics, and More
ByAinvest
Friday, Oct 10, 2025 3:34 pm ET1min read
Wall Street analysts have downgraded several top names, including Akero Therapeutics, HSBC Holdings, Doximity, Keysight Technologies, and Allogene Therapeutics. The downgrades were made by HC Wainwright & Co., Jefferies, JP Morgan, Morgan Stanley, and JP Morgan, respectively. The analysts cited various reasons for the downgrades, including concerns about the companies' growth prospects and valuation multiples.
September 12, 2025Wall Street analysts have recently downgraded several top names, including Akero Therapeutics, HSBC Holdings, Doximity, Keysight Technologies, and Allogene Therapeutics. The downgrades were made by HC Wainwright & Co., Jefferies, JP Morgan, Morgan Stanley, and JP Morgan, respectively. The analysts cited various reasons for the downgrades, including concerns about the companies' growth prospects and valuation multiples.
HC Wainwright & Co. analyst Andrew S. Fein downgraded Akero Therapeutics, Inc. (NASDAQ:AKRO) from Buy to Neutral and cut the price target from $72 to $54. This move comes amidst the announcement of Novo Nordisk's acquisition of Akero for up to $5.2 billion, which could impact the stock's valuation [2].
Jefferies analyst Joseph Dickerson downgraded the rating for HSBC Holdings plc (NYSE:HSBC) from Buy to Hold. The downgrade reflects concerns about the bank's growth prospects and valuation multiples [1].
JP Morgan analyst Alexei Gogolev downgraded Doximity, Inc. (NYSE:DOCS) from Neutral to Underweight and announced a $62 price target. The downgrade is attributed to concerns about the company's growth prospects and valuation [1].
Morgan Stanley analyst Meta Marshall downgraded Keysight Technologies, Inc. (NYSE:KEYS) from Overweight to Equal-Weight and maintained the price target of $180. The downgrade indicates a change in the analyst's view on the company's growth prospects [1].
JP Morgan analyst Brian Cheng downgraded Allogene Therapeutics, Inc. (NASDAQ:ALLO) from Neutral to Underweight. The downgrade is driven by concerns about the company's growth prospects and valuation [1].
These downgrades highlight the evolving views of Wall Street analysts on several key companies. Investors should closely monitor these developments and consider the implications for their portfolios.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet